Skip to main content

Table 1 Clinic and pathological characteristics and IHC results of 156 early stage IDCs

From: E-cadherin expression phenotypes associated with molecular subtypes in invasive non-lobular breast cancer: evidence from a retrospective study and meta-analysis

Characteristics

No. of patients (N = 156) (%)

Age (years, mean ± SD)

52.8 ± 12.0

Histologic grade

 I

13 (8.3)

 II

107 (68.6)

 III

36 (23.1)

Tumor stage

 T1

77 (49.4)

 T2

79 (50.6)

Nodal stage

 Negative

96 (61.5)

 Positive

60 (38.5)

TNM stage

 I

50 (32.1)

 II

106 (67.9)

E-cad

 Negative/low

27 (17.3)

 Positive

129 (82.7)

ER

 Negative

52 (33.3)

 Positive

104 (66.7)

PR

 Negative

82 (52.6)

 Positive

74 (47.4)

HER2

 Negative

129 (82.7)

 Positive

27 (17.3)

Ki67

 Negative

40 (25.6)

 Positive

116 (74.4)

Molecular subtypes

 Luminal A

30 (19.2)

 Luminal B

74 (47.4)

 HER2-enriched

14 (9.0)

 TNBC

38 (24.4)

  1. IHC immunohistochemistry, IDC invasive ductal carcinoma of the breast, TNBC triple-negative breast cancer